Rethinking Innateness
A Connectionist Perspective on Development Jeffrey L. Elman, Elizabeth A. Bates, Mark H. Johnson, Annette Karmiloff-Smith, Domenico Parisi and Kim Plunkett
"Rethinking Innateness asks the question, "What does it really mean to say that a behavior is innate?" The authors describe a new framework in which interactions, occurring at all levels, give rise to emergent forms and behaviors. These outcomes often may be highly constrained and universal, yet are not themselves directly contained in the genes in any domain-specific way.
One of the key contributions of Rethinking Innateness is a taxonomy of ways in which a behavior can be innate. These include constraints at the level of representation, architecture, and timing; typically, behaviors arise through the interaction of constraints at several of these levels.
The ideas are explored through dynamic models inspired by a new kind of "developmental connectionism," a marriage of connectionist models and developmental neurobiology, forming a new theoretical framework for the study of behavioral development. While relying heavily on the conceptual and computational tools provided by connectionism, Rethinking Innateness also identifies ways in which these tools need to be enriched by closer attention to biology. "
http://mitpress.mit.edu/catalog/item/default.asp?ttype=2&tid=8238

Just curious...

FDA approved a SSRI for ADHD treatment for children. But what is the difference among this new one and existing SSRIs? I will do a literature search...
http://www.strattera.com/index.html

"Differentiating AD/HD from Bipolar Disorder In Children"
http://www.childspirit.com/BDADD2001.PDF
It looks so useful and I wanted to update my website. But the server is down right now...
If you don't read PDF, find it on Google and click [View as HTML]

neurotransmitter.net
http://www.neurotransmitter.net/index.html
Another great link. It was massive amount of information on bipolar and schizophrenia. Mechanism of action and etiologies
.

"FDA recently approved a new medication for treating ADHD in children, adolescents, and adults. The new medication is called Strattera, and it is expected to be available in pharmacies early next year. I thus thought it would be useful to review a recently published study of this new drug, and discuss some issues that may be relevant when considering it as a possible treatment option. "

ATTENTION RESEARCH UPDATE http://www.helpforadd.com/2002/december.htm

Altropane™: A radio-imaging agent for the objective diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)
http://www.bostonlifesciences.com/new2.htm

Study Raises Hopes for Adhd Medical Test, more about PET Scans
http://www.adders.org/research14.htm
It does not mean that the etiology of ADHD was presented completely.I will read this stuff a bit more carefully.

"So you see the pieces of the puzzle are all beginning to fit together, which is why I think this is absolutely fascinating," R Barkley.